Gapping down
In reaction to disappointing earnings/guidance: VNR -17.2%, ROKA -7.4%, EC -2.5%, GEF -1.7%, SSL -0.7%, SSL -0.7%
Select EU bellwethers showing weakness: DB -2.8%, RBS -2.4%, IHG -2.3%, HSBC -2%, SNY -1.3%, SAN -1.1%, AZN-1.1%, GSK -1%, BCS -0.9%, SHPG -0.8%, NVS -0.7%
Other news: CLDX -50.5% (to discontinue its Phase 3 ACT IV study of RINTEGA in patients with newly diagnosed EGFRvIII-positive glioblastomane discontinued following DSMB preplanned interim analysis), SDRL -13.9% (pulling back pre-mkt after last week's 200%+ gains), PLUG -2.8% (cont weakness), PLD -1.2% (prices new investment units at JPY231,574 per unit)
Analyst comments: ROKA -7.4% (downgraded to Mkt Perform from Outperform at Leerink Partners), SSYS -4.1% (downgraded to Underweight from Neutral at JP Morgan), MU -3.9% (downgraded to Reduce from Neutral at Nomura)
In reaction to disappointing earnings/guidance: VNR -17.2%, ROKA -7.4%, EC -2.5%, GEF -1.7%, SSL -0.7%, SSL -0.7%
Select EU bellwethers showing weakness: DB -2.8%, RBS -2.4%, IHG -2.3%, HSBC -2%, SNY -1.3%, SAN -1.1%, AZN-1.1%, GSK -1%, BCS -0.9%, SHPG -0.8%, NVS -0.7%
Other news: CLDX -50.5% (to discontinue its Phase 3 ACT IV study of RINTEGA in patients with newly diagnosed EGFRvIII-positive glioblastomane discontinued following DSMB preplanned interim analysis), SDRL -13.9% (pulling back pre-mkt after last week's 200%+ gains), PLUG -2.8% (cont weakness), PLD -1.2% (prices new investment units at JPY231,574 per unit)
Analyst comments: ROKA -7.4% (downgraded to Mkt Perform from Outperform at Leerink Partners), SSYS -4.1% (downgraded to Underweight from Neutral at JP Morgan), MU -3.9% (downgraded to Reduce from Neutral at Nomura)